MAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD mice

References

• Peakman, M., and H. M. von. 2010. Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential. Diabetes. 59: 2087–2093
   PubMed Web of Science ®Google Scholar
• Axelsson, S., M. Hjorth, L. Akerman, et al. 2010. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65). Diabetes Metab. Res. Rev. 26: 559–568
   PubMed Web of Science ®Google Scholar
• Ludvigsson, J., D. Krisky, R. Casas, et al. 2012. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N. Engl. J. Med. 366: 433–442
   PubMed Web of Science ®Google Scholar
• Wherrett, D. K., B. Bundy, D. J. Becker, et al. 2011. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet. 378: 319–327
   PubMed Web of Science ®Google Scholar
• Di Lorenzo, T. P., M. Peakman, and B. O. Roep. 2007. Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes. Clin. Exp. Immunol. 148: 1–16
   PubMedGoogle Scholar
• Alleva, D. G., P. D. Crowe, L. Jin, et al. 2001. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J. Clin. Invest. 107: 173–180
   PubMed Web of Science ®Google Scholar
• Peakman, M., E. J. Stevens, T. Lohmann, et al. 1999. Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J. Clin. Invest. 104: 1449–1457
   PubMed Web of Science ®Google Scholar
• Kent, S. C., Y. Chen, L. Bregoli, et al. 2005. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature. 435: 224–228
   PubMed Web of Science ®Google Scholar
• Dardenne, M., F. Lepault, A. Bendelac, and J. F. Bach. 1989. Acceleration of the onset of diabetes in NOD mice by thymectomy at weaning. Eur. J. Immunol. 19: 889–895
   PubMedGoogle Scholar
• Muir, A., A. Peck, M. Clare-Salzler, et al. 1995. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J. Clin. Invest. 95: 628–634
   PubMed Web of Science ®Google Scholar
• Coon, B., L. L. An, J. L. Whitton, and M. G. von Herrath. 1999. DNA immunization to prevent autoimmune diabetes. J. Clin. Invest. 104: 189–194
   PubMed Web of Science ®Google Scholar
• Jaeckel, E., L. Klein, N. Martin-Orozco, and H. von Boehmer. 2003. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. J. Exp. Med. 197: 1635–1644
   PubMed Web of Science ®Google Scholar
• Thebault-Baumont, K., D. Dubois-LaForgue, P. Krief, et al. 2003. Acceleration of type 1 diabetes mellitus in proinsulin 2-deficient NOD mice. J. Clin. Invest. 111: 851–857
   PubMedGoogle Scholar
• Moriyama, H., N. Abiru, J. Paronen, et al. 2003. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc. Natl. Acad. Sci. USA. 100: 10376–10381
   PubMedGoogle Scholar
• Martin-Pagola, A., A. Pileggi, E. Zahr, et al. 2009. Insulin2 gene (Ins2) transcription by NOD bone marrow-derived cells does not influence autoimmune diabetes development in NOD-Ins2 knockout mice. Scand. J. Immunol. 70: 439–446
   Google Scholar
• Nakayama, M., N. Abiru, H. Moriyama, et al. 2005. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature. 435: 220–223
   PubMed Web of Science ®Google Scholar
• Coppieters, K. T., F. Dotta, N. Amirian, et al. 2012. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J. Exp. Med. 209: 51–60
   PubMed Web of Science ®Google Scholar
• Daniel, D., and D. R. Wegmann. 1996. Protection of nonobese diabetic mice from diabetes by intranasal or subcutaneous administration of insulin peptide B-(9-23). Proc. Natl. Acad. Sci. USA. 93: 956–960
   PubMed Web of Science ®Google Scholar
• Alleva, D. G., A. Gaur, L. Jin, et al. 2002. Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes. 51: 2126–2134
   PubMed Web of Science ®Google Scholar
• Fousteri, G., A. Dave, A. Bot, et al. 2010. Subcutaneous insulin B:9-23/IFA immunisation induces Tregs that control late-stage prediabetes in NOD mice through IL-10 and IFNgamma. Diabetologia. 53: 1958–1970
   Google Scholar
• Orban, T., K. Farkas, H. Jalahej, et al. 2010. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J. Autoimmun. 34: 408–415
   PubMed Web of Science ®Google Scholar
• Simms, M. S., D. P. Scholfield, E. Jacobs, et al. 2000. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br. J. Cancer. 83: 443–446
   PubMed Web of Science ®Google Scholar
• Ajani, J. A., J. R. Hecht, L. Ho, et al. 2006. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer. 106: 1908–1916
   PubMed Web of Science ®Google Scholar
• Gilliam, A. D., S. A. Watson, M. Henwood, et al. 2004. A phase II study of G17DT in gastric carcinoma. Eur. J. Surg. Oncol. 30: 536–543
   PubMed Web of Science ®Google Scholar
• Zhang, L., M. Nakayama, and G. S. Eisenbarth. 2008. Insulin as an autoantigen in NOD/human diabetes. Curr. Opin. Immunol. 20: 111–118
   PubMed Web of Science ®Google Scholar
• Babaya, N., E. Liu, D. Miao, et al. 2009. Murine high specificity/sensitivity competitive europium insulin autoantibody assay. Diabetes Technol. Ther. 11: 227–233
   PubMed Web of Science ®Google Scholar
• Zhang, L., J. M. Barker, S. Babu, et al. 2007. A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1. Clin. Immunol. 125: 131–137
   PubMedGoogle Scholar
• Arif, S., T. I. Tree, T. P. Astill, et al. 2004. Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health. J. Clin. Invest. 113: 451–463
   PubMed Web of Science ®Google Scholar
• Tian, J., M. A. Atkinson, M. Clare-Salzler, et al. 1996. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J. Exp. Med. 183: 1561–1567
   PubMed Web of Science ®Google Scholar
• Achenbach, P., K. Koczwara, A. Knopff, et al. 2004. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J. Clin. Invest. 114: 589–597
   PubMedGoogle Scholar
• Groux, H., A. O'Garra, M. Bigler, et al. 1997. A CD4 + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 389: 737–742
   PubMed Web of Science ®Google Scholar
• Sakaguchi, S. 2004. Naturally arising CD4 + regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531–562
   PubMed Web of Science ®Google Scholar
• O'Shea, J. J., A. Ma, and P. Lipsky. 2002. Cytokines and autoimmunity. Nat. Rev. Immunol. 2: 37–45
   PubMed Web of Science ®Google Scholar
• Liu, E., N. Abiru, H. Moriyama, et al. 2002. Induction of insulin autoantibodies and protection from diabetes with subcutaneous insulin B:9-23 peptide without adjuvant. Ann. N. Y. Acad. Sci. 958: 224–227
   PubMed Web of Science ®Google Scholar
• Devendra, D., J. Paronen, H. Moriyama, et al. 2004. Differential immune response to B:9-23 insulin 1 and insulin 2 peptides in animal models of type 1 diabetes. J. Autoimmun. 23: 17–26
   Google Scholar
• Liu, E., H. Moriyama, J. Paronen, et al. 2003. Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulin autoantibodies following insulin peptide B:9-23 immunization in the NOD mouse. J. Autoimmun. 21: 213–219
   PubMed Web of Science ®Google Scholar
• Bot, A., D. Smith, S. Bot, et al. 2001. Plasmid vaccination with insulin b chain prevents autoimmune diabetes in nonobese diabetic mice. J. Immunol. 167: 2950–2955
   PubMed Web of Science ®Google Scholar
• Yu, L., D. Miao, L. Scrimgeour, et al. 2012. Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay. Diabetes. 61: 179–186
   Google Scholar
• Liu, B., J. L. Frost, J. Sun, et al. 2013. MER5101, a novel abeta1-15:DT conjugate vaccine, generates a robust anti-abeta antibody response and attenuates abeta pathology and cognitive deficits in APPswe/PS1DeltaE9 transgenic mice. J. Neurosci. 33: 7027–7037
   Google Scholar
• Wing, K., and S. Sakaguchi. 2010. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11: 7–13
   PubMed Web of Science ®Google Scholar
• Staeva-Vieira, T., M. Peakman, and H. M. von. 2007. Translational mini-review series on type 1 diabetes: immune-based therapeutic approaches for type 1 diabetes. Clin. Exp. Immunol. 148: 17–31
   PubMed Web of Science ®Google Scholar
• Wing, K., and S. Sakaguchi. 2010. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 11: 7–13
   PubMed Web of Science ®Google Scholar
• Tonkin, D. R., J. He, G. Barbour, and K. Haskins. 2008. Regulatory T cells prevent transfer of type 1 diabetes in NOD mice only when their antigen is present in vivo. J. Immunol. 181: 4516–4522
   PubMedGoogle Scholar
• Bisikirska, B. C., and K. C. Herold. 2005. Regulatory T cells and type 1 diabetes. Curr. Diab. Rep. 5: 104–109
   Google Scholar
• Grinberg-Bleyer, Y., A. Baeyens, S. You, et al. 2010. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J. Exp. Med. 207: 1871–1878
   PubMed Web of Science ®Google Scholar